Mayo Clinic | Strategic Alliance Partners

Sikander Ailawadhi, MD, discusses the ongoing evaluation of cemsidomide in relapsed/refractory multiple myeloma.

Mayo Clinic shows thymus preps CD8 T cells and uncovers molecular structures of PKCβ, a protein linked to cancer, refining immunotherapy.

Mayo Clinic scientists have revealed the molecular structures of PKCβ, a key protein linked to cancer and neurological diseases.

Mayo Clinic researchers are advancing brain tumor care through molecular profiling, improved diagnostics for younger patients, new drug delivery methods, and emerging immunotherapies.

Daniel H. Ahn, DO, discusses research surrounding the combination of atebimetinib and modified gemcitabine and nab-paclitaxel (Abraxane) in pancreatic cancer.

Mark D. Tyson, II, MD, MPH, discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC.

Mark D. Tyson, II, MD, MPH, discusses how TARA-002 could fit into the treatment landscape of BCG-naive NMIBC.

Mark D. Tyson, II, MD, MPH, discusses efficacy data with TARA-002 in patients with BCG-naive high-grade non–muscle-invasive bladder cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses how the REDMOD AI model could help identify prediagnostic pancreatic cancer on CT scans missed by radiologists.

Mayo Clinic researchers are advancing brain tumor care through molecular profiling, improved diagnostics for younger patients, new drug delivery methods, and emerging immunotherapies.

Mayo Clinic researchers developed a blood-based method that may help detect germ cell tumors.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors.

Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone.

Chemo therapy delivered in the home of patients has shown feasibility and safety according to researchers at Mayo Clinic

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma.

A new study suggests that blocking the survival response after PARP inhibitor treatment could bolster their efficacy in ovarian cancer.

Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US.

Mayo Clinic researchers identified a previously unrecognized way lung tumors weaken the immune system.

A Mayo Clinic study demonstrated how treatment sequencing may affect survival in early-stage pancreatic cancer.

Mayo Clinic Comprehensive Cancer Center is expanding surgical options for patients undergoing treatment or risk-reducing procedures for breast cancer.

Mayo Clinic’s Department of Radiation Oncology has developed an AI monitoring tool to support clinicians in monitoring for prostate cancer recurrence.

MedEduChat, an EHR-integrated AI agent provided individualized prostate cancer education for patients according to researchers at Mayo Clinic.

MD Anderson and SOPHiA GENETICS announce a partnership focused on data-driven oncology tools for clinical practice.

Cardiac surgery and airway reconstruction successfully treated rare cancer that spread to a patient's heart according to researchers at Mayo Clinic.

Ayalew Tefferi, MD, tirelessly advances medicine, driven by a philosophy that physical and intellectual journeys are one.

Patients were able to better manage symptoms with digital check-ins and remote care according to researchers at the Mayo Clinic.

Proton beam therapies can result in strong outcomes for patients with throat cancer according to Mayo Clinic researchers.

Dual-antibody, off-the-shelf therapy showed deep durable responses in patients with extra medullary multiple myeloma according to Mayo Clinic researchers.

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Mayo Clinic researchers have found previously unknown genetic and cellular processes that occur in lung cancers that respond well to immunotherapy.